--- In a large China real-world study of 281 heavily pretreated, predominantly high-risk patients with relapsed/refractory plasma cell neoplasms, FUCASO achieved a 95.9% objective response rate, a 77.2% CR/sCR rate, and a 94.1% MRD negativity rate --- with…
— Late-breaking oral presentation of first-in-human data (LBA-11) showed that a single intravenous infusion of IASO206 generated functional BCMA CAR-T cells in vivo without lymphodepleting chemotherapy. The study demonstrated a 90% objective response rate and a 90% MRD…
National class action firm Edelson Lechtzin LLP is offering free case evaluations to individuals affected by the MedImpact Healthcare Systems data breach, which may have exposed names, Social Security numbers, and sensitive health information.SAN DIEGO, Sept. 26, 2026…